BIO.B vs. BIO, AVTR, PKI, RVTY, TXG, PACB, ILMN, VTRS, TFX, and LEGN
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (PKI), Revvity (RVTY), 10x Genomics (TXG), Pacific Biosciences of California (PACB), Illumina (ILMN), Viatris (VTRS), Teleflex (TFX), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Bio-Rad Laboratories vs.
Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
In the previous week, Bio-Rad Laboratories had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 8 mentions for Bio-Rad Laboratories and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.69 beat Bio-Rad Laboratories' score of -0.15 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.
Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Bio-Rad Laboratories has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 64.3% of Bio-Rad Laboratories shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bio-Rad Laboratories received 223 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.80% of users gave Bio-Rad Laboratories an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
Bio-Rad Laboratories has a consensus target price of $653.00, indicating a potential upside of 72.30%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.
Summary
Bio-Rad Laboratories beats Bio-Rad Laboratories on 10 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools